Dyne Therapeutics, Inc.
DYN
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.5B
$24.28
▼ -2.69%
P/E
-7.29
Mkt Cap
$4.5B
52-Wk Range
$11.92–$27.31
52-Week Range
$11.92 - $27.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 82.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary FORCE platform technology for targeted muscle disease therapeutic delivery
- Focused pipeline addressing genetically driven muscle diseases with high unmet medical needs
- Experienced management team with deep expertise in muscle biology and rare disease development
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial advancement and potential regulatory approvals for lead programs
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+44.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DYN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 30, 2026
Reported EPS of -$1.08 vs -$0.75 consensus (-44.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-44.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 17, 2026
vs Industry
How DYN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related